180 Life Sciences Corp.
ATNF
$1.07
-$0.01-0.93%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -66.01% | -56.02% | -50.05% | -30.86% | 10.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -63.94% | -50.89% | -43.40% | -24.70% | 5.65% |
| Operating Income | 63.94% | 50.89% | 43.40% | 24.70% | -5.65% |
| Income Before Tax | 92.85% | 71.68% | 59.58% | 43.82% | -174.14% |
| Income Tax Expenses | 99.87% | -149.22% | -149.22% | -149.22% | -49,713.64% |
| Earnings from Continuing Operations | 92.28% | 75.71% | 63.95% | 48.52% | -153.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.28% | 75.71% | 63.95% | 48.52% | -153.64% |
| EBIT | 63.94% | 50.89% | 43.40% | 24.70% | -5.65% |
| EBITDA | 64.17% | 51.19% | 43.65% | 24.83% | -5.49% |
| EPS Basic | 98.19% | 93.47% | 89.21% | 81.36% | -68.62% |
| Normalized Basic EPS | 94.13% | 87.71% | 54.30% | -223.64% | -335.76% |
| EPS Diluted | 98.18% | 93.47% | 89.21% | 81.36% | -68.29% |
| Normalized Diluted EPS | 94.13% | 87.71% | 54.30% | -223.54% | -335.79% |
| Average Basic Shares Outstanding | 213.46% | 275.01% | 285.22% | 278.57% | 171.22% |
| Average Diluted Shares Outstanding | 213.46% | 275.01% | 285.22% | 278.48% | 171.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
